Oral Oresentation 8

4:12 PM - 4:18 PM JST(7:12 AM - 7:18 AM UTC)

[O08-08] Long-Term Efficacy and Safety of Tulisokibart in Participants with Ulcerative Colitis: The Open-Label Extension of the Phase 2 ARTEMIS-UC Study

*Wen Zhou¹, Christopher Ma², Sami Hoque³, Miles P. Sparrow⁴, Jaclyn K. Anderson¹, Mark Yen⁵, Bin Dong¹, Brian G. Feagan⁶, Bruce E. Sands⁷ (1. Merck & Co., Inc., Rahway, NJ, USA, 2. Division of Gastroenterology & Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada, 3. Department of Gastroenterology, Barts Health NHS Trust, London, UK, 4. Department of Gastroenterology, School of Translational Medicine, Monash University and Alfred Health, Melbourne, VIC, Australia, 5. Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, 6. Departments of Medicine, Epidemiology, and Biostatistics, Western University, London, ON, Canada, 7. Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA)

Password required to view

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.